Evidence map›Paper›PMID 39456150›Full record

ArticleBiomolecules2024

T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.

Iole Macchia, Valentina La Sorsa, Alessandra Ciervo, Irene Ruspantini, Donatella Negri, Martina Borghi, Maria Laura De Angelis, Francesca Luciani, Antonio Martina, Silvia Taglieri and 4 more

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Iole MacchiaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-3870-8202
Valentina La SorsaResearch Promotion and Coordination Service, Istituto Superiore di Sanità, 00161 Rome, Italy.
Alessandra CiervoDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-0664-9375
Irene RuspantiniCore Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.
Donatella NegriDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-3437-9288
Martina BorghiDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.
Maria Laura De AngelisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0003-4220-8822
Francesca LucianiNational Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-1362-2808
Antonio MartinaNational Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, 00161 Rome, Italy.
Silvia TaglieriDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0009-0008-1939-4982
Valentina DurastantiNeurology Unit, San Filippo Neri Hospital, ASL RM1, 00135 Rome, Italy.
Maria Concetta AltavistaNeurology Unit, San Filippo Neri Hospital, ASL RM1, 00135 Rome, Italy.
Francesca UrbaniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-5522-2706
Fabiola ManciniDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Funding

Istituto Superiore di Sanità ISS/DON12/2021
6 · The paper itself

Abstract

COVID-19 remains a significant threat, particularly to vulnerable populations. The emergence of new variants necessitates the development of treatments and vaccines that induce both humoral and cellular immunity. This study aimed to identify potentially immunogenic SARS-CoV-2 peptides and to explore the intricate host-pathogen interactions involving peripheral immune responses, memory profiles, and various demographic, clinical, and lifestyle factors. Using in silico and experimental methods, we identified several CD8-restricted SARS-CoV-2 peptides that are either poorly studied or have previously unreported immunogenicity: fifteen from the Spike and three each from non-structural proteins Nsp1-2-3-16. A Spike peptide, LA-9, demonstrated a 57% response rate in ELISpot assays using PBMCs from 14 HLA-A*02:01 positive, vaccinated, and mild-COVID-19 recovered subjects, indicating its potential for diagnostics, research, and multi-epitope vaccine platforms. We also found that younger individuals, with fewer vaccine doses and longer intervals since infection, showed lower anti-Spike (ELISA) and anti-Wuhan neutralizing antibodies (pseudovirus assay), higher naïve T cells, and lower central memory, effector memory, and CD4hiCD8low T cells (flow cytometry) compared to older subjects. In our cohort, a higher prevalence of Vδ2-γδ and DN T cells, and fewer naïve CD8 T cells, seemed to correlate with strong cellular and lower anti-NP antibody responses and to associate with Omicron infection, absence of confusional state, and habitual sporting activity.

Indexed as

COVID-19COVID-19 VaccinesHost-Pathogen InteractionsSARS-CoV-2AdultAgedAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesEpitopes, T-LymphocyteFemaleHumansMaleMiddle AgedPeptidesSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopes, T-LymphocytePeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2bioinformaticsCOVID-19ELISpotneutralizing antibodiesT cell epitopesT peptide

Identifiers

PMID39456150
PMCPMC11505848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.